 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- || XC101-D13H / Xoc Pharma
Enrollment closed, Trial completion date, Trial primary completion date: Single Ascending Dose Study to Investigate the Safety and Pharmacokinetics of XC101-D13H in Healthy Adult Subjects (clinicaltrials.gov) - Sep 23, 2021
P1, N=32, Active, not recruiting, Sponsor: Xoc Pharmaceuticals
Recruiting --> Active, not recruiting | Trial completion date: Jan 2020 --> Mar 2022 | Trial primary completion date: Dec 2019 --> Jan 2022
- || XC130 / Xoc Pharma
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Single Ascending Dose Study Investigating the Safety, Tolerability, and PK of XC130-A10H in Healthy Adult Subjects (clinicaltrials.gov) - Sep 23, 2021
P1, N=56, Active, not recruiting, Sponsor: Xoc Pharmaceuticals
Recruiting --> Active, not recruiting | Trial completion date: Jan 2020 --> Mar 2022 | Trial primary completion date: Dec 2019 --> Jan 2022 Recruiting --> Active, not recruiting | N=40 --> 56 | Trial completion date: Jan 2020 --> Apr 2022 | Trial primary completion date: Jan 2020 --> Jan 2022
- XC130 / Xoc Pharma, Dopergin (lisuride) / Bayer
[VIRTUAL] Assessment of a Novel Long Lasting Dopamine Agonist in the Unilateral 6-OHDA Lesion Model of Parkinson’s Disease () - Mar 18, 2021 - Abstract #AAN2021AAN_1450;
Recruiting --> Active, not recruiting | N=40 --> 56 | Trial completion date: Jan 2020 --> Apr 2022 | Trial primary completion date: Jan 2020 --> Jan 2022 The evaluation of XC130-A10H in the unilateral 6-OHDA model strongly suggests that XC130-A10H could be an important novel addition to therapy throughout the time course of Parkinson’s disease.
- XC130 / Xoc Pharma, Dopergin (lisuride) / Bayer, Permax (pergolide) / Eli Lilly
[VIRTUAL] In Vitro Profile of a Novel Long Lasting Dopamine Agonist Designed to Optimize Efficacy and Safety () - Mar 18, 2021 - Abstract #AAN2021AAN_1435;
Key in vitro safety and efficacy indicators are assessed and contrasted with the reference dopamine agonist compounds, lisuride and pergolide. The in vitro receptor activity profile shows that XC130-A10H could represent an important addition to the therapeutic armamentarium throughout the time course of Parkinson’s disease.
- XC101-D13H / Xoc Pharma
[VIRTUAL] Development of a Novel, Clinical-stage Drug for the Prevention of Migraine Based on Receptor Activity Mapping and Achievement of a Target Receptor Profile () - Mar 18, 2021 - Abstract #AAN2021AAN_1114;
Xoc developed a novel clinical stage compound, XC101-D13H, with the desired target receptor profile for safe and effective migraine preventive therapy. XC101-D13H entered human clinical trials in 2019.
- ||||| XC101-D13H / Xoc Pharma
Adverse events: Great talk by @alanrapoport : XC101-D13H doesn't affect 5HT2A/B and alpha so doesn't have the methysergide fibrotic, psychotic, CV side effects #HCNE2020boston (Twitter) - Nov 7, 2020
- XC101-D13H / Xoc Pharma
[VIRTUAL] Interim Results of a Phase 1 Single Ascending Dose Study of XC101-D13H, a Novel Compound for the Prevention of Migraine () - Jul 15, 2020 - Abstract #AHS2020AHS_185;
In the early cohorts of this Phase 1 study, XC130-D13H was well tolerated and showed suitable pharmacokinetics for daily oral dosing. The receptor profile and initial clinical results support the prospect that XC101-D13H can prevent migraine without inducing the most important serotonergic agonist-driven side effects.
- XC130 / Xoc Pharma, Dopergin (lisuride) / Bayer, Permax (pergolide) / Eli Lilly
In-vitro Profile of a Novel Long Lasting Dopamine Agonist Designed to Optimize Efficacy and Safety () - Feb 3, 2020 - Abstract #AAN2020AAN_5047;
Key in-vitro safety and efficacy indicators are assessed and contrasted with the reference dopamine agonist compounds, lisuride and pergolide... The in-vitro receptor activity profile suggests that XC130-A10H could represent an important addition to the therapeutic armamentarium throughout the time course of Parkinson’s disease.
- XC101-D13H / Xoc Pharma
Development of a Novel Drug for the Prevention of Migraine based on Receptor Activity Mapping and Achievement of a Target Receptor Profile () - Jan 21, 2020 - Abstract #AAN2020AAN_1436;
Xoc developed a target receptor profile for effective migraine preventive therapeutics and a novel clinical stage compound, XC101-D13H. XC101-D13H entered human clinical trials in 2019.
- | XC101-D13H / Xoc Pharma
New P1 trial: Single Ascending Dose Study to Investigate the Safety and Pharmacokinetics of XC101-D13H in Healthy Adult Subjects (clinicaltrials.gov) - Sep 25, 2019
P1, N=32, Recruiting, Sponsor: Xoc Pharmaceuticals
- | XC130 / Xoc Pharma
New P1 trial: Single Ascending Dose Study Investigating the Safety, Tolerability, and PK of XC130-A10H in Healthy Adult Subjects (clinicaltrials.gov) - Aug 1, 2019
P1, N=40, Recruiting, Sponsor: Xoc Pharmaceuticals